<DOC>
	<DOCNO>NCT00820872</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Lapatinib may stop growth tumor cell block enzymes need cell growth . Giving docetaxel together carboplatin , trastuzumab , lapatinib may kill tumor cell . PURPOSE : This phase II trial study side effect give docetaxel together carboplatin , trastuzumab , lapatinib treat patient early stage breast cancer .</brief_summary>
	<brief_title>Docetaxel , Carboplatin , Trastuzumab , Lapatinib Treating Patients With Early Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability ( include rate diarrhea ) adjuvant therapy comprise docetaxel , carboplatin , trastuzumab ( Herceptin® ) , lapatinib ditosylate patient early-stage breast cancer . Secondary - Evaluate adverse event profile regimen patient . - Evaluate LVEF patient receive regimen . OUTLINE : Patients receive docetaxel IV 60 minute carboplatin IV 30 minute day 1 , trastuzumab ( Herceptin® ) IV 30-90 minute day 1 , 8 , 15 , oral lapatinib ditosylate day 1-21 ( TCHL ) . Treatment TCHL repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients receive trastuzumab IV 30-90 minute day 1 oral lapatinib ditosylate day 1-21 ( day 1-7 course 12 ) ( LT ) . Treatment LT repeat every 3 week 12 course absence disease progression unacceptable toxicity.. After completion study treatment , patient follow every 6 month 2 year annually 8 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary invasive adenocarcinoma breast fulfil follow criterion : Nonmetastatic disease Operable adequately excise Patients nonresectable deep margin invasion eligible provide receive radiotherapy region Patients histologically document infiltration skin ( pT4 ) eligible provide undergone receive radiotherapy encompass tumor bed Nodepositive OR negative determine eligible receive adjuvant trastuzumab ( Herceptin® ) No positive suspicious internal mammary node SNS irradiate No supraclavicular lymph node involvement ( confirm fine needle aspiration biopsy ) Over expression and/or amplification HER2 invasive component primary tumor , accord one following : 3+ overexpression IHC ( &gt; 30 % invasive tumor cell ) 2+ 3+ ( 30 % le neoplastic cell ) overexpression IHC AND situ hybridization ( FISH/CISH ) test demonstrate HER2 gene amplification HER2 gene amplification FISH/CISH ( &gt; 6 HER2 gene copy per nucleus , FISH ratio [ HER2 gene copy chromosome 17 signal ] &gt; 2.2 . ) Negative equivocal overall result ( FISH test ratio &lt; 2.2 , &lt; 6.0 HER2gene copy per nucleus ) staining score 0 , 1+ , 2+ , 3+ ( 30 % le neoplastic cell ) IHC allow Hormone receptor status know ( estrogen receptor without progesterone receptor ) PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 01 Hemoglobin ≥ 10.0 g/dL ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 2.0 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 1.5 time ULN ( ≤ 2.0 time ULN know Gilbert syndrome ) Baseline LVEF ≥ 50 % measure ECHO MUGA scan Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious cardiac illness medical condition include , limited , follow : History document congestive heart failure ( NYHA class ) systolic dysfunction ( LVEF &lt; 50 % ) Highrisk uncontrolled arrhythmia ( e.g. , ventricular tachycardia , highgrade atrioventricularblock [ second degree high ] , supraventricular arrhythmia adequately ratecontrolled ) Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension ( read systolic BP &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg ) No concurrent serious disease may interfere plan treatment include severe pulmonary condition illness None following : Ulcerative colitis Malabsorption syndrome Any disease significantly affect gastrointestinal function Inability swallow oral medication PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior mediastinal irradiation except internal mammarynode irradiation present breast cancer No prior antiHER2 therapy reason No prior biologic immunotherapy breast cancer No prior resection stomach small bowel No concurrent anticancer therapy include chemotherapeutic agent , biologic agent , radiotherapy No concurrent anticancer treatment another investigational trial hormone therapy immunotherapy unless approve study chair No concurrent CYP3A4 inhibitor inducers No concurrent epoetin alfa , include darbepoetin alfa No concurrent oprelvekin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>